

## **REPORT AND RECOMMENDATIONS FROM THE NOMINATION COMMITTEE IN SOFTOX SOLUTIONS AS TO THE GENERAL MEETING TO BE HELD ON 27<sup>th</sup> June 2025.**

The Nomination Committee currently includes:

- Kristian Almås
- Bjørn Larsen

### **1. PROPOSALS for The Annual General Meeting 27<sup>th</sup> of June 2025**

#### **Election of Members to the Board of Directors**

With reference to the stock notice 30 May 2025 the board members Eskil Zapffe and Henrik J. Nielsen have resigned from the Board, effective 30th of May 2025.

We propose to re-elect Ulrik Spork (Chair), Christian Vinding Thomsen (Vice Chair) and Adrian Bignami (Board member) for the period until the Annual General Meeting in 2026.

To strengthen the Board in the Clinical area we proposing to elect Tore Duvold, PhD. as new Board Member for the period until the Annual General Meeting in 2026.

CVs for the proposed Board Member is attached to this Notice.

The new candidate is independent from shareholders and the company's management.

The proposal from the Nomination Committee is based on a careful evaluation of the Board's composition and function versus the company needs. It is our belief that the proposed Board is suited to help meeting the Company needs present and up to the ordinary AGM in 2026.

#### **Proposal of REMUNERATION OF BOARD MEMBERS**

Nominal remuneration:

Chairman: NOK 500 000 annually.

Vice Chairman: NOK 320 000 annually.

Other Board Members: NOK 125 000 annually.

#### **Warrant/Option Programme**

The company must enter into an agreement that includes, among other things, management and the members of the board, where, within the current and/or future authority of the board, it must be possible to give warrants or options to employees for the acquisition of shares, limited at all times to 10% of the company's registered share capital.

## Members Nomination Committee

We suggest re-electing the members of the Nomination Committee

- Kristian Almås
- Bjørn Larsen


for the period until the Annual General Meeting in 2026.

\* \* \*

Oslo, 11<sup>th</sup> June 2025

On behalf of the Nomination Committee

SIGN

Signed by:  
  
7C77C8527D3F475...

Kristian Almås

**Tore Duvold (born , Norwegian nationality)**

Tore Duvold, a Norwegian national, brings over 20 years of experience in the biotech and pharmaceutical industries, specializing in drug discovery, development, innovation, and strategic leadership. He has held significant roles, including Vice President for Drug Discovery at LEO Pharma, and leadership positions at Edvince, Innovationsfonden Danmark, and Aker Biopharma. Currently, he is the CEO of Spermosens AB and holds multiple board memberships, using his expertise to guide emerging biotech and pharma companies. Duvold focuses on pioneering diagnostic solutions and leading R&D initiatives, while playing a crucial role in establishing strategic partnerships and collaborations that drive business growth and scientific innovation.

**Special Competencies:** Leadership in drug discovery and innovation, strategic partnerships, and pharmaceutical sector growth, supported by a robust scientific background.

He holds a PhD in bioorganic chemistry from Université Louis Pasteur, which provides a solid foundation for his work in advanced scientific and industrial settings.